A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations
Details
Age
Child to Adult
Type of Study
Treatment
Locations
University of Colorado Hospital
Principal Investigator
Laura Medina, MD
Study ID
Protocol Number: 21-3431
More information available at ClinicalTrials.gov: NCT04985604
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers